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Abstract Ceramide, a product of sphingomyelin metabolism, is
a novel lipid second messenger that mediates diverse cellular
functions. The present study demonstrates the activation of
caspase-3/CPP-32L, during apoptosis induced by cell permeable
exogenous ceramides, in AK-5 tumor, a spontaneously regressing
rat histiocytoma. The apoptotic events were suppressed by the
caspase-3 specific tetrapeptide inhibitor DEVD-CHO but not by
the caspase-1 inhibitor YVAD-CMK. In cells overexpressing
Bcl-2, a significant decrease in cell death was observed after
exogenous addition of ceramides. Furthermore the processing of
caspase-3 to its active form upon apoptotic stimulus, and the
subsequent cleavage of the substrate PARP, suggested a central
role for caspase-3 in the ceramide mediated apoptosis in AK-5
tumor cells.
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1. Introduction
Apoptosis is a cell autonomous death process requiring the
orchestrated participation of endogenous cellular enzymes for
the dismantling of the cell and to maintain cellular homeo-
stasis. Recent investigations have identi¢ed several ICE/CED-
3 related proteases, called ‘caspases’ [1] which play a crucial
role in the execution of apoptosis. These include caspase-2
(NEDD-2/ICH-1), caspase-3 (CPP32L/YAMA/Apopain), cas-
pase-4 (TX/ICH-2/ECIrelII), caspase-5 (ICErelIII), caspase-6
(Mch-2), caspase-7 (Mch-3/CMH-1/ICE-LAP3), caspase-8
(FLICE/MACH/Mch-5), caspase-9 (ICE-LAP6/Mch-6) and
caspase-10 (Mch-4) (reviewed in [2]). All the members of the
caspase family are cysteine proteases that possess the unusual
ability to cleave substrates after aspartate residues. These pro-
teases are synthesized as precursors which, upon receiving the
apoptotic signals, are processed to active enzymes that dis-
mantle the cell in an apoptotic cascade.
Ceramide, a product of sphingomyelin hydrolysis (reviewed
in [3]), is considered a second messenger with pleiotropic ef-
fects. Increased levels of ceramide have been correlated with
cell cycle arrest [4], terminal di¡erentiation [5], cellular senes-
cence [6], and apoptotic processes [7]. Work by Flores et al.
demonstrated a dual role for ceramide, both protective and
inductive in apoptosis [8]. The mechanism by which ceramide
induces such cellular e¡ects is poorly understood. Intense in-
terest has focused on the potential involvement of diverse
signaling processes in the regulation of ceramide mediated
apoptosis.
Work in our laboratory has been focused on dissecting the
molecular events involved in the cell death of AK-5 tumor, a
spontaneously regressing rat histiocytoma [9]. We have earlier
reported that apoptosis in AK-5 cells is induced by NK cells
[10] and an unidenti¢ed factor present in the serum from AK-
5 tumor rejecting animals. Both in vivo [11] and in vitro [12]
studies demonstrate the role of speci¢c caspases in tumor cell
apoptosis and their functional redundancy.
The present study shows the selective involvement of cas-
pase-3 [13], in tumor cell apoptosis, upon induction with cell
permeable exogenous ceramides, the C2-ceramide (natural)
and the C8-ceramide (synthetic), which is con¢rmed by the
cleavage of poly(ADP-ribose) polymerase [14], the key cellular
substrate of caspase-3. Tumor cells overexpressing the Bcl-2
gene suppressed the apoptotic e¡ects of ceramide. The addi-
tion of a caspase-3 speci¢c peptide inhibitor blocked the acti-
vation of caspase-3 and the subsequent cell death, suggesting
that the activation of caspase-3 plays an essential role in the
process of apoptosis, in AK-5 tumor cells following ceramide
treatment.
2. Materials and methods
2.1. Animals and tumor
AK-5 tumor was maintained as ascites in an inbred colony of Wis-
tar rats by injecting 5U106 tumor cells i.p. Animals which had been
injected with tumor cells (5U106) subcutaneously and had rejected the
tumor were used as the source for the anti-AK-5 serum. We have used
a single cell clone of AK-5 adapted to grow in vitro, called BC-8, in
all the studies, to avoid ambiguity in results due to tumor heteroge-
neity [15]. BC-8 cells were grown in suspension in DMEM supple-
mented with 10% (v/v) heat inactivated fetal calf serum in an atmos-
phere of 95% air and 5% CO2. Cell viability was assessed by the
trypan blue dye exclusion assay. The serum from tumor rejecting
animals (immune serum) was used as a speci¢c inducer of apoptosis
(known positive control).
2.2. Ceramide treatment
AK-5 cells (2U106) in DMEM-FCS were treated with C2-ceramide
isolated from bovine brain (30 WM ¢nal concentration) or C8-ceram-
ide (Calbiochem) (40 WM concentration) for 8 h, at 37‡C in a CO2
incubator. The cells were washed and used for analysis.
2.3. Fluorescence microscopy
The normal and apoptotic cells were washed with PBS and ¢xed in
80% methanol. Cells were washed twice with PBS and stained with
propidium iodide reagent (propidium iodide, Calbiochem, 50 Wg/ml in
0.1% sodium citrate containing 0.1% Triton X-100) and observed
under a £uorescence microscope (Nikon Optiphot).
2.4. DNA extraction and electrophoresis
Cells were washed and suspended in citrate phosphate bu¡er, and
the fragmented DNA was extracted following the previously pub-
lished procedure [16]. Fragmented DNA with the loading bu¡er was
electrophoresed on 0.8% agarose gel at 2 V/cm for 16 h. The DNA in
the gel was visualized under UV after staining with 5 Wg/ml ethidium
bromide.
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2.5. Western analysis
Samples were electrophoresed on a 10% SDS-polyacrylamide gel for
3 h at 30 mA. Separated proteins were transferred to a nitrocellulose
membrane (Hybond C; Amersham Corp.) and probed with an appro-
priate dilution of the primary antibody for PARP and CPP32 respec-
tively. The immune complex was detected using alkaline phosphatase
conjugated anti-rabbit antibody.
2.6. Fluorogenic assays
The activities of ICE-like and CPP32-like proteases were assayed as
described earlier [17]. Brie£y, 106 cells were lysed in lysis bu¡er (1%
Triton X-100, 0.32 M sucrose, 5 mM EDTA, 10 mM Tris-HCl, pH 8,
2 mM DTT, 1 mM PMSF, 1 Wg/ml aprotinin, 1 Wg/ml leupeptin) for
15 min at 4‡C followed by centrifugation (20 000Ug) for 5 min. ICE-
like and CPP32-like activities were detected in the supernatants by
measuring the proteolytic cleavage of the £uorogenic substrates
YVAD-AMC and DEVD-AMC [18] respectively in assay bu¡er
(100 mM HEPES, 10% sucrose, 0.1% CHAPS, 2 mM DTT, 1 mM
PMSF, 1 Wg/ml aprotinin, 1 Wg/ml leupeptin) using an excitation
wavelength of 380 nm and an emission wavelength of 460 nm.
2.7. Inhibitor competition experiments
Speci¢city for caspase-3-like activity was demonstrated by inhibi-
tion with DEVD-CHO, a speci¢c tetrapeptide inhibitor for caspase-3-
like proteases [19]. Aliquots containing 50 Wg of protein were prein-
cubated with increasing concentrations of DEVD-CHO for 30 min,
followed by the addition of the £uorescent substrate and further in-
cubation for 1 h at 30‡C and the caspase-3 activity was determined.
3. Results and discussion
3.1. Ceramide induces apoptosis in AK-5 cells
Cell permeable analogues of ceramides were able to induce
typical morphological changes of apoptosis in a time depend-
ent manner, such as cell shrinkage, membrane blebbing and
ru¥ing, chromatin condensation, formation of apoptotic
bodies, as assessed by propidium iodide staining (Fig. 1).
C2-ceramide induced apoptosis at 30 WM concentration and
was more potent and induced high levels of apoptosis within
7^8 h, whereas C8-ceramide, used at 40^50 WM concentration,
required longer incubation times. At higher concentrations,
the apoptotic e¡ect of ceramide declined, and cells showed
morphological features of necrosis. The speci¢city of ceram-
ides was con¢rmed using dihydroceramide, a structural ana-
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Fig. 1. Propidium iodide staining of AK-5 cells, after treatment
with (B) 30 WM C2-Cer, (C) 50 WM C8-Cer, (D) 75 WM dihydrocer-
amide; A: control BC-8 cells.
Fig. 2. Internucleosomal DNA cleavage of BC-8 cells as observed
on 0.8% agarose gel stained with ethidium bromide. BC-8 cells
treated with 1 WM dexamethasone (lane 2), 10% immune serum
(lane 3), 30 WM C2-Cer (lane 4), 50 WM C8-Cer (lane 5). Lane 1
represents control cells. Dexamethasone and immune serum are
known positive controls.
Fig. 3. Quantitative determination of apoptosis in BC-8 cells. Apop-
tosis was determined after staining cells with propidium iodide and
£ow cytometry. (1) Control cells, (2) cells treated with 30 WM C2-
Cer, (3) cells pretreated with 200 WM YVAD-CMK for 1 h followed
by treatment with C2-Cer, (4) cells pretreated with 50 WM DEVD-
CHO for 1 h followed by treatment with C2-Cer, (5) cells treated
with 50 WM C8-Cer, (6) cells pretreated with 200 WM YVAD-CMK
for 1 h followed by treatment with C8-Cer, (7) cells pretreated with
50 WM DEVD-CHO for 1 h followed by treatment with C8-Cer, (8)
Bcl-2 gene transfected AK-5 cells treated with 30 WM C2-Cer. Bars
represent S.E.M.
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logue of ceramide, which lacks the C4^C5 trans double bond
in the sphingolipid backbone, and failed to induce apoptosis
(Fig. 1D) [20].
The fragmentation of DNA and formation of a character-
istic ladder pattern, a hallmark of apoptosis [21], was con-
¢rmed by agarose gel electrophoresis of the fragmented
DNA. A characteristic ladder pattern was visible after 6 h
of treatment with ceramides, which was absent in uninduced
cells (Fig. 2). The pattern produced was similar to that ob-
tained from BC-8 cells treated with serum factor, a known
trigger of apoptosis.
The role of caspases in ceramide induced apoptosis was
assessed using caspase speci¢c tetrapeptide inhibitors. Cells
were pretreated with YVAD-CMK and DEVD-CHO, non-
cleavable derivatives of the natural recognition site for cas-
pase-1 and caspase-3-like proteases respectively [19], prior to
the treatment with ceramide, and analyzed by £ow cytometry.
DEVD-CHO treated cells showed a marked reduction in
apoptotic morphology whereas YVAD-CMK was ine¡ective
(Fig. 3). This suggests a speci¢c role for DEVD dependent
protease in ceramide induced apoptosis. Cells overexpressing
the Bcl-2 gene, a mammalian homolog of Ced-9 in Caenorhab-
ditis elegans [22], were resistant to apoptosis induced by cer-
amides. This suggests that Bcl-2 is downregulating a key event
in the apoptotic cascade, prior to the caspase activation.
3.2. Processing of caspase-3
Caspase-3 is synthesized in the cells as a 32 kDa proenzyme,
and upon receiving a speci¢c apoptotic stimulus, it is proc-
essed to an active form of 17 kDa. Immunoblotting experi-
ments showed the speci¢c processing of caspase-3 in ceramide
treated cells using a monoclonal antibody for caspase-3, p17
subunit (Fig. 4). A marginal level of caspase-3 processing was
observed in the untreated cells. The signal corresponding to
the processed form of 17 kDa appears to be fainter probably
due to the fact that not all cells in any induced culture are
undergoing apoptosis at one time point because of heteroge-
neity in cell cycle events. Further, since caspase-3 acts in an
autocatalytic mode, a lower concentration of the active en-
zyme may be su⁄cient to trigger the downstream cascade of
apoptotic events.
3.3. Fluorogenic enzyme assays
The activation of speci¢c caspases was also assessed using
£uorogenic peptide substrates for ICE and CPP-32 respec-
tively. An increase in DEVD dependent protease activity
was readily detectable within 1 h of induction of apoptosis,
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Fig. 5. Determination of DEVD dependent and YVAD dependent protease activities in cells treated with (A) 30 WM C2-Cer and (B) 50 WM
C8-Cer for di¡erent time intervals. Caspase activity is expressed as relative £uorescence units.
Fig. 6. Inhibition of DEVD dependent protease activity in ceramide
treated cell extracts pretreated with various concentrations of the
caspase-3 inhibitor DEVD-CHO. Caspase activity is expressed as
relative £uorescence units.
Fig. 4. Immunoblot showing the proteolytic processing of caspase-3/
CPP32 by exogenous ceramides. Processing of the 32 kDa proform
of caspase-3 to the 17 kDa active form by 1 WM dexamethasone
(lane 2), 10% immune serum (lane 3), 30 WM C2-Cer (lane 4), and
50 WM C8-Cer (lane 5). Lane 1 represents untreated BC-8 cells. The
faint extra band present in all the lanes is of a non-speci¢c nature.
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which is several fold higher in the induced extract than in the
uninduced one (Fig. 5), whereas there was no detectable
YVAD dependent protease activity. The low level of
DEVD-AMC cleavage activity in untreated cells may be a
consequence of the low percentage of apoptotic cells in the
normal cell population. These results indicate that DEVD
dependent protease activity is responsible for apoptotic char-
acteristics induced by the ceramides. The lack of involvement
of caspase-1 in the induction of apoptosis is not surprising,
given the fact that caspase-1 knockout mice do not show a
general defect in apoptosis [23,24] whereas disruption of the
caspase-3 gene in knockout mice a¡ects the morphogenetic
cell death in the central nervous system, leading to abnormal
brain development [25].
We next examined whether the activation of caspase-3 is
inhibited by DEVD-CHO, its speci¢c inhibitor. In our experi-
ments pretreatment of the extracts with 1 WM DEVD-CHO
totally blocked AMC liberation, and about 50% inhibition
was obtained with a dose of 10 nM (Fig. 6).
3.4. Cleavage of PARP
In order to con¢rm the involvement of caspase-3-like pro-
tease in the induction of apoptosis in AK-5 tumor cells, the
cleavage of the DNA repair enzyme PARP [14] and endoge-
nous substrate of caspase-3 was monitored. Immunoblotting
with a polyclonal antibody for PARP showed the speci¢c
cleavage of PARP to its signature fragment of 85 kDa (Fig.
7). Proteolytic cleavage of PARP precludes the catalytic do-
main of PARP from being recruited to the sites of DNA
damage and presumably disables PARP from coordinating
subsequent genome maintenance.
It is known that in the family of caspases, caspase-3 has the
highest sequence homology and substrate speci¢city to Ced-3,
the prototype cell death gene in nematodes [13]. It is also
activated by a variety of agents that induce apoptosis
[26,27], which was also proved in a cell-free system [19].
Overall these studies have established that caspase-3 is a
key player during ceramide induced apoptosis in AK-5 tumor
cells, and inhibition of caspase-3 activity blocks apoptosis.
Furthermore, the results suggest that caspase-1 does not
play a signi¢cant role, as is true in other systems. This implies
that the mechanisms leading to the activation of distinct cas-
pases are highly speci¢c and redundant. The AK-5 tumor
model may provide insight into the tissue speci¢c expression
of caspases in tumors and their regulatory mechanisms.
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Fig. 7. Immunoblot showing the cleavage of PARP to the 85 kDa
fragment upon treatment of cells with immune serum (lane 3), 30
WM C2-Cer (lane 4), 50 WM C8-Cer (lane 5). Lanes 1 and 2 repre-
sent untreated control cells and cells treated with dihydroceramide,
respectively.
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